Phaseline

Targets › GAD1

GAD1 (Glutamate decarboxylase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Oct 2029.

Catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with pyridoxal 5'-phosphate as cofactor..; FUNCTION: [Isoform 3]: Enzymatically inactive as glutamate decarboxylase. (UniProt, Q99259)

Open in Phaseline: the race on GAD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MeiraGTxAAV-GAD
Glutamic acid decarboxylase (GAD) gene transfer via adeno-associated virus
GAD1Phase 1Parkinson's DiseaseOct 2029

Conditions

Parkinson's Disease (1)

Modalities

other (1)

Companies

MeiraGTx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.